Generic Name:
encorafenib
Project Status:
Complete
Therapeutic Area:
Metastatic colorectal cancer
Manufacturer:
Pfizer Canada ULC
Brand Name:
Braftovi
Project Line:
Reimbursement Review
Project Number:
PC0233-000
Tumour Type:
Gastrointestinal
NOC Status at Filing:
Pre NOC
Details
Manufacturer Requested Reimbursement Criteria1:
In combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, after prior therapy.
Submission Type:
Initial
Companion Diagnostics:
Yes
Fee Schedule:
Schedule A
Indications:
In combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, after prior therapy.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.